Nishida Y, Sakakibara K, Kano T, Ohta M, Tomoda Y
Nihon Sanka Fujinka Gakkai Zasshi. 1986 Jul;38(7):1017-25.
Immunotherapy for malignant ovarian tumors has been discussed in a number of recent studies. However, the effects of this therapy are produced by an indirect mechanism, and are, therefore, difficult to evaluated. In order to select appropriate cases for immunotherapy using OK-432 against malignant ovarian tumors, clinical and experimental studies were carried out. Clinically patients with ovarian cancer were divided into two groups; OK-432 treated group and no immunotherapy groups. As a parameter of immunoresponse to OK-432, PHA and Su-PS skin tests were performed periodically. Natural killer (NK) cell activity was also measured before and after administration of OK-432. Peripheral blood lymphocyte subsets were analysed by using monoclonal antibody and a laser flow cytometer. Finally tumor growth velocity was evaluated in tumor transplanted nude mice. The survival rate was used as an index for evaluation. The survival rate of the OK-432 treated groups was better than the control groups in advanced cases, but a statistically significant difference was found between the two groups. Among fundamental studies which were carried out to select appropriate cases, Su-PS skin test, the NK response of OK-432 seemed to be actually utilized.
近期的多项研究探讨了恶性卵巢肿瘤的免疫疗法。然而，这种疗法的效果是通过间接机制产生的，因此难以评估。为了选择使用OK-432对恶性卵巢肿瘤进行免疫治疗的合适病例，开展了临床和实验研究。临床上，卵巢癌患者被分为两组：OK-432治疗组和未进行免疫治疗组。作为对OK-432免疫反应的参数，定期进行PHA和Su-PS皮肤试验。在给予OK-432之前和之后还测量了自然杀伤（NK）细胞活性。使用单克隆抗体和激光流式细胞仪分析外周血淋巴细胞亚群。最后，在肿瘤移植裸鼠中评估肿瘤生长速度。生存率用作评估指标。在晚期病例中，OK-432治疗组的生存率优于对照组，但两组之间未发现统计学上的显著差异。在为选择合适病例而进行的基础研究中，Su-PS皮肤试验表明OK-432的NK反应似乎得到了实际利用。
